A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02032277 |
Recruitment Status :
Completed
First Posted : January 10, 2014
Last Update Posted : January 20, 2021
|
Sponsor:
AbbVie
Collaborators:
German Breast Group
NSABP Foundation Inc
Grupo Español de Investigación del Cáncer de Mama
US Oncology Research
Information provided by (Responsible Party):
AbbVie
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | March 18, 2016 |
Actual Study Completion Date : | November 12, 2020 |
Certification/Extension First Submitted : | March 2, 2017 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):